Korean J Nephrol.  1999 Jan;18(1):73-84.

Prognostic Factors of Diffuse Proliferative Lupus Nephritis

Affiliations
  • 1Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

Abstract

Diffuse proliferative lupus nephritis(DPLN) is the most severe form in lupus nephritis. We retrospectively analyzed 90 DPLN patients who were confirmed by kidney biopsy and treated at least for 12 months to compare the effectiveness of treatment modalities and to investigate the prognostic factors of DPLN. The patients were categorized as intravenous cyclophosphamide pulse(CY) group and oral corticosteroid(with or without cytotoxic drug; PO) group. When CY group(69pts) and PO group(21pts) were compared, there was no differences between two groups in sex, age, follow-up months, chronicity index(CI, 4.55 vs 3.76; CY vs PO, respectively), complications of treatment, mortality rate(4.3% vs 0%), remission rate of nephritis(at 3 year; 59.1% vs 75.5%) and renal survival rate(at 5 years; 88.0% vs 91.7%), b ut significant differences in frequency of nephrotic syndrome(66.7% vs 33.3%) and azotemia (30.4% vs 0%), activity index(7.14 vs 4.33) and relapse rate(2.9% vs 42.9%). When remission group (49pts) and nonremission group(41pts) were compared, the CI, initial azotemia, tubular atrophy, glomerular sclerosis, sex and duration of nephritis were prognostic factors for remission in univariate analysis, and CI(OR, 9.89) and sex(OR, 10.99) in multivariate analysis. When remission group(35pts) and nonremission(34pts) group were compared in CY group, the CI, initial azotemia and tubular atrophy were the prognostic factors in univariate analysis, and CI(OR, 7.69) in multivariate analysis. The initial azotemia was the only prognostic factor for renal survival. We concluded that the CI, sex and initial azotemia were the prognostic factors for renal remission and survival, but the treatment modality was not in DPLN. Therefore it is necessary to evaluate the prognostic factors before decision of treatment modality.

Keyword

Diffuse proliferative lupus nephritis; Systemic lupus erythematosus; therapy; Prognosis; Cyclophosphamide

MeSH Terms

Atrophy
Azotemia
Biopsy
Cyclophosphamide
Follow-Up Studies
Humans
Kidney
Lupus Erythematosus, Systemic
Lupus Nephritis*
Mortality
Multivariate Analysis
Nephritis
Prognosis
Recurrence
Retrospective Studies
Sclerosis
Cyclophosphamide
Full Text Links
  • KJN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr